What are the contraindications to Dasatinib/Startaxed?

Dasatinib (Dasatinib) is a second-generation BCR-ABL tyrosine kinase inhibitor, mainly used for the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), in which the mutation is Philadelphia chromosome positive. During clinical medication consultation, many patients will focus on whether there are “clear contraindications” to dasatinib. From the perspective of overseas drug instructions and international guidelines, dasatinib does not have broad contraindications in an absolute sense, but this does not mean that risk assessment can be ignored for its use.

In medical practice, the so-called "no clear contraindications" refers more to the fact that there are no groups strictly prohibited from use like some chemotherapy drugs, and it does not apply to all patients. Dasatinib is a targeted drug with a relatively powerful mechanism of action and has inhibitory effects on multiple kinase pathways. Therefore, a comprehensive assessment of the patient's overall condition is usually required before use. Overseas clinical consensus emphasizes that patients who have had severe allergic reactions to dasatinib ingredients in the past should avoid using it again. This is a basic principle common to any drug.

In addition, dasatinib may have certain effects on the cardiopulmonary and hematopoietic systems during its metabolism in the body. Therefore, in clinical practice, patients with severe uncontrolled heart disease, active severe infection, or extremely impaired bone marrow function usually need to carefully weigh whether to use this drug. Although such situations are not strictly defined as "contraindications", they often constitute medication restrictions in actual decision-making. Overseas guidelines prefer to classify these situations as "risk groups that require high vigilance."

For patients with chronic myelogenous leukemia and acute lymphoblastic leukemia, the use of dasatinib emphasizes the principle of individualization. The doctor will make a comprehensive judgment based on the disease stage, previous treatment response, and comorbidities.

Reference materials:https://www.drugs.com/dasatinib.html